Walgreen to vote on merger with Alliance Boots

The 8,200-store chain would expand to 11,000 locations operating in 10 countries, if shareholders approve.

PBM deal on new hep.-C cocktail highlights drugmaker tolerance for discounts

PBM deal on new hep.-C cocktail highlights drugmaker tolerance for discounts

The agreement between AbbVie and Express Scripts is seen as a seismic shift in the joint development of cost-effective therapies, and gives the new regimen a slight edge on Gilead's popular remedies.

GSK shingles vax shaping up to compete with Merck's

GSK shingles vax shaping up to compete with Merck's

The Herpes zoster vaccine candidate showed relatively strong efficacy in a Phase-III trial, but its dosing is less convenient than an older product sold by rival Merck.

Five things for pharma marketers to know: Monday, December 22

Five things for pharma marketers to know: Monday, December 22

Express Scripts taps AbbVie hep. C drug as exclusive option; AZ first-in-class cancer drug approved; Cubist gains OK for superbug fighter.

Five things for pharma marketers to know: Friday, December 19

Five things for pharma marketers to know: Friday, December 19

Roche strikes out in cancer, Alzheimer's trials; Lilly in pact for fast-acting insulin; Humana revamps formulary.

Pfizer bets on Duchenne MD treatment

Pfizer bets on Duchenne MD treatment

The company moves on three leading contenders in the muscular dystrophy segment with the start of a Phase II trial

OPDP slams print ad in Untitled Letter

OPDP slams print ad in Untitled Letter

The FDA's prescription drug promotion arm wrote that the professional print ad for seizure med Aptiom "misleadingly overstated its efficacy."

Apotex challenges Amgen blockbuster Neulasta

Canadian firm presents FDA with its third biosimilar application.

Merck buys Swiss biotech

The drugmaker announced it will acquire OncoEthix and its oncology candidate OTX015 in a deal worth up to $365 million

Five things for pharma marketers to know: Thursday, December 18

Five things for pharma marketers to know: Thursday, December 18

Shire may bid on NPS Pharmaceuticals; Amgen says cancer drug will cost $178,000; Takeda has a new head of R&D.


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters